Maxim Group analyst Jason McCarthy has maintained their bullish stance on APRE stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors, including the emerging clinical profile of APR-1051 and Aprea’s solid financial position. He highlights that APR-1051, a WEE1 inhibitor, has shown early signs of anti-tumor activity, including a confirmed partial response in uterine carcinosarcoma and additional evidence of disease control, while maintaining a favorable safety and tolerability profile that compares well versus competing agents.
He also notes that the company’s cash balance, recently strengthened by a $30M equity raise, provides sufficient runway to advance the Phase 1 program and generate further data, including at upcoming ASCO presentations. McCarthy’s model assumes eventual commercialization of APR-1051 in uterine serous carcinoma and platinum-resistant ovarian cancer, with an 80% risk adjustment applied, and he maintains a $5 price target, reflecting meaningful upside potential from current levels.
McCarthy covers the Healthcare sector, focusing on stocks such as Moleculin Biotech, Aprea Therapeutics, and Gain Therapeutics. According to TipRanks, McCarthy has an average return of -14.2% and a 32.87% success rate on recommended stocks.
In another report released today, Wedbush also reiterated a Buy rating on the stock with a $6.00 price target.